Table 3 Characteristics of all patients.
No. | Sex | Age | ARONJ stage | Jaw | Primary disease | ARD | Administration route of ARD | Medication period of ARD (months) | Risk factor for ARONJ |
|---|---|---|---|---|---|---|---|---|---|
1 | F | 90 | 2 | Mandible | OP | Risedronate | Intraoral | 6 | DM |
2 | F | 79 | 3 | Mandible | OP | Risedronate | Intraoral | 24 | DM |
3 | F | 81 | 2 | Mandible | OP | Risedronate | Intraoral | 36 | none |
4 | F | 79 | 2 | Mandible | OP | Alendronate | Intraoral | 20 | DM |
5 | M | 75 | 3 | Mandible | BM (PC) | Zoledronate | Intravenous | 22 | DM |
6 | F | 67 | 3 | Maxilla | BM (BC) | Zoledronate | Intravenous | 66 | none |
7 | F | 58 | 2 | Mandible | BM (BC) | Zoledronate | Intravenous | 53 | none |
8 | F | 76 | 2 | Mandible | BM (BC) | Zoledronate | Intravenous | 46 | none |
9 | F | 78 | 3 | Maxilla | NPS | Alendronate | Intraoral | 66 | Steroid |
10 | M | 80 | 2 | Mandible | RA | Alendronate | Intraoral | 48 | Steroid |
11 | F | 78 | 3 | Mandible | RA | Risedronate | Intraoral | 36 | Steroid |
12 | F | 63 | 1 | Mandible | RA | Alendronate | Intraoral | 60 | MTX |
13 | F | 76 | 2 | Mandible | RA | Risedronate | Intraoral | 60 | Steroid |
14 | F | 77 | 1 | Mandible | RA | Alendronate | Intraoral | 120 | MTX |
15 | F | 66 | 1 | Maxilla | RA | Risedronate | Intraoral | 120 | Steroid MTX |
